{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:50:07Z","timestamp":1786971007844,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T00:00:00Z","timestamp":1443052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.yebeh.2015.09.006","type":"journal-article","created":{"date-parts":[[2015,9,27]],"date-time":"2015-09-27T09:45:13Z","timestamp":1443347113000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"PA","title":["Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials"],"prefix":"10.1016","volume":"52","author":[{"given":"Victor","family":"Biton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gil-Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouko","family":"Isojarvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Doty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2058-0308","authenticated-orcid":false,"given":"Nathan B.","family":"Fountain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2015.09.006_bb0005","article-title":"US prescribing information","author":"VIMPAT\u00ae (lacosamide)","year":"2014"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0010","article-title":"Summary of product characteristics","author":"VIMPAT\u00ae (lacosamide)","year":"2014"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s13318-012-0093-x","article-title":"Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration","volume":"37","author":"Cawello","year":"2012","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1528-1167.2012.03725.x","article-title":"Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment","volume":"54","author":"Cawello","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000339077","article-title":"Bioequivalence of intravenous and oral formulations of the antiepileptic drug lacosamide","volume":"90","author":"Cawello","year":"2012","journal-title":"Pharmacology"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nurt.2006.10.002","article-title":"Lacosamide","volume":"4","author":"Doty","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P01.077","article-title":"Low lacosamide plasma protein binding in lacosamide-naive patients (abstract)","volume":"78","author":"Fountain","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0040","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0091270009347675","article-title":"No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers","volume":"50","author":"Cawello","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0045","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1177\/0091270011426875","article-title":"No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers","volume":"52","author":"Cawello","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0050","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0055","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0065","article-title":"Population pharmacokinetics of lacosamide in subjects with partial-onset seizures: results from two phase III trials (abstract)","volume":"72","author":"Nickel","year":"2009","journal-title":"Neurology"},{"issue":"1 Suppl. 1","key":"10.1016\/j.yebeh.2015.09.006_bb0070","first-page":"97","article-title":"Lacosamide has no effect on the enzymatic activity of CYP3A4","volume":"12","author":"Cawello","year":"2012","journal-title":"Epilepsy Currents"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0075","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/epi.12192","article-title":"Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin","volume":"54","author":"Stockis","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0080","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/epi.12085","article-title":"Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers","volume":"54","author":"Cawello","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0085","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40261-014-0177-2","article-title":"Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial","volume":"34","author":"Cawello","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40261-014-0180-7","article-title":"Effect of lacosamide on the steady-state pharmacokinetics of digoxin: results from a phase I, multiple-dose, double-blind, randomised, placebo-controlled, crossover trial","volume":"34","author":"Cawello","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0095","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jpain.2007.02.157","article-title":"Low potential for drug\u2013drug-interaction of lacosamide (abstract)","volume":"8","author":"Thomas","year":"2007","journal-title":"J Pain"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1528-1167.2012.03407.x","article-title":"Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a phase III open-label extension trial","volume":"53","author":"Husain","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.yebeh.2014.09.074","article-title":"Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8years","volume":"41","author":"Rosenfeld","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0110","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/11586830-000000000-00000","article-title":"Examining the clinical utility of lacosamide: pooled analyses of three phase II\/III clinical trials","volume":"24","author":"Chung","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0115","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14737175.9.1.33","article-title":"Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures","volume":"9","author":"Beydoun","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1528-1167.2012.03589.x","article-title":"The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Zaccara","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.yebeh.2011.08.032","article-title":"Add-on lacosamide: a retrospective study on the relationship between serum concentration, dosage, and adverse events","volume":"22","author":"Hillenbrand","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yebeh.2010.10.002","article-title":"Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction?","volume":"20","author":"Novy","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0140","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0145","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/01.wnl.0000302370.01359.8f","article-title":"Monotherapy in adults and elderly persons","volume":"69","author":"Faught","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0150","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11065-007-9043-9","article-title":"Neuropsychological and behavioral effects of antiepilepsy drugs","volume":"17","author":"Loring","year":"2007","journal-title":"Neuropsychol Rev"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0155","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11910-010-0120-8","article-title":"Update on anticonvulsant drugs","volume":"10","author":"Chong","year":"2010","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0160","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1212\/01.wnl.0000345667.45642.61","article-title":"Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy","volume":"72","author":"Perucca","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0165","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.yebeh.2012.11.052","article-title":"The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting","volume":"26","author":"Helmstaedter","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.09.006_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/ane.12414","article-title":"Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures","author":"Rudd","year":"2015","journal-title":"Acta Neurol Scand"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015005211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015005211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T15:58:58Z","timestamp":1668787138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505015005211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":34,"alternative-id":["S1525505015005211"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.09.006","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}